
Unclench your jaw: Why everyone is grinding their teeth right now — including you
I did my best not to feel offended. 'Sorry,' I mumbled, rubbing my aching massester muscles.
I'm one of the 8 to 10% of the UK population that grinds their teeth in some way — and I'm betting, you are too.
I'm not entirely sure when it started, but these days, I'm all-too-aware that I do it pretty much every night.
I've woken myself up one-too-many times by accidentally biting down on my tongue (yes, it really hurts) and when my alarm goes off, I open my eyes with an aching jaw.
The habit seeps into my waking hours too. I'll suddenly become aware that my jaw is clenched, as though that's its default position.
I once heard (e.g. watched a TikTok video) that the three-finger test is a quick way to asses your jaw mobility. If you can fit three stacked fingers between your upper and lower reeth, you're in the normal range. I can only just about do it.
But bruxism, the umbrella term for teeth-grinding or jaw clenching, does more than just make your jaw ache. In fact, it can cause a whole host of issues, from dental problems and headaches, to pain in the face, neck or shoulders, and TMJ disorders.
To put it mildly, teeth grinding is no picnic — and it's even more annoying when you consider that you're most likely doing it subconciously.
And while the current estimates would suggest that around 6.7 million Brits deal with condition, it seems to be on the rise.
Post-pandemic, a USA-based 2021 survey among dentists found that 70% reported an increase in patients grinding and clenching their teeth.
More recently, the hashtag #teethgrinding on TikTok has a staggering 262.9 million views, while #unclencyourjaw has 37.7 million. You can even buy tshirts and artwork on Etsy emblazoned with the phrase 'unclench your jaw'.
And dentist Dr Sahil Patel, of London's Marylebone Smile Clinic, tells Metro that he's seeing an increasing number of patients displaying signs of bruxism.
'Well developed jaw muscles show as a squarer facial appearance or stronger jawline,' he explains. 'And, on the teeth themselves, bruxism causes accelerated tooth wear and breakage, making teeth look shorter, squarer and yellower. Tooth sensitivity and gum recession can also be a sign.'
Why have we become a nation unable to relax our faces?
While it's not always clear why people do it, stress and anxiety is a well-observed cause. 'Our patients are absoloutely more stressed than ever,' Dr Sahil says.
'They may not always disclose it to us, but we can sense when someone is stressed. We're seeing it more with younger people.'
Mental Health UK's annual Burnout Report, released in January 2025, found that one in three adults either 'always or often' experience high or extreme levels of pressure or stress, while nine in 10 say they've experienced it at some point over the last year.
Mind also found that women are more likely than men to experience common mental health problems (20.7% of women compared to 13.2% of men affected), with young women aged 16 to 24 at the highest risk. It's worth nothing that women are also more likely to experience bruxism, particularly when they're awake.
Experts are pretty much in agreement that society is increasinly stressful. Chartered psychologist, Dr Manpreet Dhuffar-Pottiwal says we live an era of 'uncertainty and instability'.
She tells Metro: 'Political unrest, economic fluctuations, and environmental crises result in an unpredictability which leaves people feeling out of control regarding their futures.'
Our 'always-online' culture, particularly experienced by younger generations also doesn't help, as Dr Manpreet says we face 'technological overload.'
'Social media platforms promote curated representations of life, leading us to measure their worth against others. Additionally, urbanisation has contributed to a disconnection from nature. People confined to busy city lives miss out on the calming effects of the natural world.'
Workplace pressures have changed too. 'The rise of remote work and gig economies has introduced ambiguity about job security and increased workloads,' says Dr Manpreet.
'Many young employees, striving for stability in uncertain times, experience burnout and chronic stress as they juggle multiple responsibilities.
'Rigid schedules and the lack of work-life balance lead many to neglect self-care practices.'
And finally, as ever, the global pandemic plays a part. Dr Manpreet says: 'It heightened health-related anxieties, with individuals increasingly focused on personal safety.
'This ongoing concern can create a cycle of stress that affects various facets of life.
'It's no surprise that there's a growing prevalence of conditions like bruxism.'
What are the options for treating jaw clenching?
So, aside from taking an indefinite holiday to escape the stressors of daily life, what can we do to relieve all this tension?
According to Dr Sahil, your dentist can help. 'We can't manage your stress, but we can do a few things to manage the symptoms,' he says.
'Night guards can cushion the contact between the teeth during the night, or reainers, which are thinner, are designed to keep the teeth in their position and protect from night grinding.
'They come in many different forms and materials, but the ballpark cost for these is between £250 and £500.'
Alternatively, nurse prescriber and aesthetic trainer, Natalja Andrejeva, says that Botox is an 'emerging go-to solution' for teeth-grinding.
'Over the past few years, I've seen a noticeable rise in clicents seeking relief from bruxism using Botox, especially post-pandemic,' she tells Metro.
'Botox is injected into the masseter muscles to relax them. This reduces the intensity of clenching and grinding without affecting your ability to chew or speak.'
The result? 'Less jaw tension, fewer headaches, and better sleep and quality of life. You'll also get a slightly slimmer jawline,' adds Natalja, founder of Face Code Aesthetic, where she offers the treatment, starting at £290.
'Typically, treatment would be required every three to six months, depending on muscle strength and individual response.
'But over time, some clients find they can space out treatments more as the habit and symptoms lessen.'
Of course, the ultimate — and almost impossible solution — is to live a stress-free life. But until then, be safe in the knowledge that you're far from the only one — and don't forget to unclench your jaw.
Do you have a story to share?

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


The Independent
7 minutes ago
- The Independent
WeightWatchers boss says ‘exciting work to do' amid impact of weight loss jabs
WeightWatchers was slower to adapt to the emergence of anti-obesity jabs than rivals, its boss has admitted, as the 62-year-old brand strives to catch up with rapidly evolving attitudes towards weight loss. Tara Comonte, chief executive of the US-based business, said it had a lot of work to do after going through a 'reset'. WeightWatchers recently announced it had emerged from bankruptcy after writing off a portion of the 1.15 billion US dollar (£860 million) debt on its balance sheet. It came as the business was competing with the emergence of GLP-1s – the scientific term for weight loss jabs, which work by reducing food cravings – and a new wave of apps and advice spreading on social media. Ms Comonte told the PA news agency that it 'wasn't as quick to medical weight loss solutions' as some other firms in the US, notably so-called 'telehealth' businesses that offer healthcare remotely. WeightWatchers, which runs some 20,000 workshops each month globally, is now 'at the beginning of the journey' towards forging a new place in the industry and meeting demand from current and future members, Ms Comonte said. 'This whole industry is going through somewhat of a reset and we have exciting work to do,' she told the PA news agency. 'This is a moment where, possibly more than ever before, people are talking about weight, and weight health… where people are seeking more education than ever before, and there are more voices than ever before.' Ms Comonte said the brand was known for 'trust and science' and it was important to harness that 'as there are more and more voices in the ecosystem'. WeightWatchers recently partnered with anti-obesity drugs provider CheqUp in the UK so patients taking the medication can access its 'companion' diet and lifestyle support app. It forms part of its efforts to muscle into the market by offering behavioural strategies and community-based support to people using or coming off the medication. 'There's no 'us and them' anymore,' Ms Comonte told PA, hitting back at weight loss jabs often being pitted as rivals to its model. Dr Kim Boyde, WeightWatchers' newly appointed chief medical officer, said not all its members will want or need weight loss medication – but stressed that it was 'imperative' the programme offers it to those that might benefit. Recent estimates suggest that about 1.5 million people in the UK are taking weight loss jabs. Health officials have suggested that they can help to turn the tide on obesity, but have stressed they are not a silver bullet and do come with side effects.


Reuters
an hour ago
- Reuters
Roche to investigate whether new drug can delay or prevent Alzheimer's disease
July 27 (Reuters) - Swiss drugmaker Roche Holding (ROG.S), opens new tab plans to investigate whether an experimental medicine can delay or prevent Alzheimer's disease symptoms, it said on Sunday, as a part of the company's growing development programme for the disease. The clinical trial of the drug, Trontinemab, will target people who are at risk of cognitive decline and will aim to delay or prevent the symptoms of Alzheimer's, Roche said in a statement. Trontinemab is designed so that the drug is transported across the blood brain barrier—protective blood vessels that prevent chemicals in the bloodstream from entering the brain — in hopes of delivering more of the treatment to the brain. Rivals like Eli Lilly (LLY.N), opens new tab have been making progress in the complicated field of Alzheimer's recently, with Lilly's drug Kisunla getting a recommendation for approval for certain patients from the European Medicines Agency last week. Kisunla is already approved in the U.S. Treatments for Alzheimer's approved so far, including Eisai (4523.T), opens new tab and Biogen's (BIIB.O), opens new tab Leqembi and Lilly's Kisunla, are designed to clear sticky clumps of a protein called amyloid beta in the brain. They carry hefty price tags as well as the risk of serious brain swelling and bleeding.


Reuters
3 hours ago
- Reuters
Roche to test if new drug can prevent Alzheimer's disease, Bloomberg News reports
July 27 (Reuters) - Swiss drugmaker Roche Holding (ROG.S), opens new tab plans to test whether an experimental medicine can prevent Alzheimer's disease symptoms in high-risk people, Bloomberg News reported on Sunday. The new late-stage study will target people who are at risk of cognitive decline and aim to slow down the emergence of symptoms or prevent them fully, the report said, citing a statement. The new pre-clinical study is the third largest late-stage trial that the company has announced for its drug trontinemab, which uses an experimental technology called brain shuttle to ferry medicine past the protective blood-brain barrier, according to the report. Rivals like Eli Lilly (LLY.N), opens new tab have been making progress in the complicated field of Alzheimer's recently with Lilly's Alzheimer's drug Kisunla getting recommendation from the European Medicines Agency (EMA) last week. Reuters could not immediately verify the report. Roche did not immediately respond to a request for a comment. Treatments for Alzheimer's approved so far, including Eisai (4523.T), opens new tab and Biogen's (BIIB.O), opens new tab Leqembi, and Eli Lilly's Kisunla, are designed to clear sticky clumps of a protein called amyloid beta in the brain. They also carry hefty price tags and the risk of serious brain swelling and bleeding.